Korean Circ J.  2010 May;40(5):243-246. 10.4070/kcj.2010.40.5.243.

Simultaneous Multi-Vessel Subacute Stent Thromboses in Zotarolimus-Eluting Stents

• Kim YH
• Suh SY
• Kim SH
• Lim SY
• Roh SY
• Kim JB
• Song WH
• Ahn JC

• KMID: 1456370
• DOI: http://doi.org/10.4070/kcj.2010.40.5.243

Abstract

Despite its low incidence, stent thrombosis (ST) is one of the most dreaded complications of percutaneous coronary intervention. Endeavor (Medtronics Europe SA) is a new zotarolimus-eluting stent (ZES) with a favorable safety profile that was reported in early and ongoing trials. However, few lethal stent thromboses related to this new drug eluting stent (DES) have been reported. We experienced a case of simultaneous subacute ZES thromboses, 6 days after stent implantations in the proximal left anterior descending artery and the proximal right coronary artery (RCA).

Keyword

Zotarolimus; Drug-eluting stents; Stents; Thrombosis

MeSH Terms

Arteries
Coronary Vessels
Drug-Eluting Stents
Europe
Incidence
Percutaneous Coronary Intervention
Sirolimus
Stents
Thrombosis
Sirolimus

Figure

• 

  Fig. 1 Coronary angiogram showing critical stenosis in the proximal LAD (A) and the proximal segment of the RCA (B); recovered luminal patency after revascularization with zotarolimus-eluting stents in each artery (C and D). LAD: left anterior descending coronary artery, RCA: right coronary artery.

• 

  Fig. 2 Coronary angiogram showing total occlusion of the stents in the proximal LAD and proximal RCA 6 days after implantation (A and B). After balloon angioplasty, blood flow recovered to TIMI 3 (C and D). LAD: left anterior descending coronary artery, RCA: right coronary artery, TIMI: Thrombolysis in Myocardial Infarction.

Reference

1. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007. 356:1020–1029.

2. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007. 50:463–470.

3. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006. 47:2108–2111.

4. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006. 114:798–806.

5. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006. 48:2440–2447.

6. Korovesis S, Giazitzoglou E, Katritsis DG. Subacute thrombosis following implantation of zotarolimus-eluting stent. Hellenic J Cardiol. 2006. 47:310–312.

7. Zhang F, Oian J, Ge J. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent. J Invasive Cardiol. 2008. 20:423–425.

8. Kim SH, Kim EJ, Suh SY, et al. Cardiogenic shock caused by simultaneous subacute stent thrombosis after implantation of sirolimus-eluting stents. Int J Cardiol. 2007. 120:423–425.

9. Moon JY, Chung JW, Kim JH, Ahn YK, Jeong MH. Simultaneous subacute stent thrombosis of two sirolimus-eluting stents in a patient treated by ReoPro, thrombus aspiration and triple anti-platelet agents. Int J Cardiol. 2008. 130:e25–e29.

10. Park JS, Kim YJ, Shin DG, et al. Clinical and angiographic outcome of sirolimus-eluting stent for the treatment of very long lesions. Korean Circ J. 2006. 36:490–494.

11. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004. 109:3171–3175.